Brief: Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
20/05/2025 13:55
May 20 (Reuters) - Tempus AI Inc TEM.O: TEMPUS AI : PARTNERS WITH VERASTEM TO DEVELOP CDX FOR FDA-APPROVED KRAS-MUTANT RECURRENT LOW-GRADE OVARIAN CANCER COMBINATION TREATMENT Source text: ID:nBwTjLjNa Further company coverage: TEM.O ((Reuters.Briefs@thomsonreuters.com;))